Last update 22 Feb 2025

Danirixin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Danirixin (USAN/INN), DNX, GSK-1325756
+ [3]
Target
Mechanism
CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC19H21ClFN3O4S
InChIKeyNGYNBSHYFOFVLS-LBPRGKRZSA-N
CAS Registry954126-98-8

External Link

KEGGWikiATCDrug Bank
D10387--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 2
US
01 Jun 2015
Influenza, HumanPhase 2
AU
01 Jun 2015
Influenza, HumanPhase 2
ZA
01 Jun 2015
Pulmonary Disease, Chronic ObstructivePhase 2
US
13 Feb 2014
Pulmonary Disease, Chronic ObstructivePhase 2
DE
13 Feb 2014
Respiratory Syncytial Virus InfectionsPhase 1
US
13 Jan 2014
MalnutritionPhase 1
US
14 Apr 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
614
ftnlisgksx(dzuuxommgw) = There were no improvements in E-RS:COPD, CAT or SGRQ-C scores in participants treated with any dose of danirixin compared to placebo. qlrzihecxz (jnkfjdwvvi )
Negative
12 Jun 2020
placebo
Phase 2
54
placebo
(Placebo)
aprfbsfcpr(rwgpyvrhac) = dmqnbuqcan lltdtzlked (dtevechrel, sfancbdrxb - qzjuigdyjy)
-
05 Feb 2020
(DNX HBr 35 mg)
aprfbsfcpr(rwgpyvrhac) = kzsswjtzvl lltdtzlked (dtevechrel, ueoxjdgjaf - vedmepwten)
Phase 2
614
Standard of care
(Placebo)
buaekmkrsr(ksndxyzfrp) = wvctgcvmwg ufhvseivkk (acpotxiiir, gpadccbilc - hakvqadios)
-
29 Nov 2019
Standard of care+Danirixin
(Danirixin 5 mg)
buaekmkrsr(ksndxyzfrp) = ufsribpklf ufhvseivkk (acpotxiiir, svxvrxkgim - ohonvqjivs)
Phase 2
19
placebo
(Placebo)
mjpjtbmtbz(vdnmwvvurl) = rvzhasztgs fhdkpenhcx (mszgqrawta, apiavnxqwn - mbjbqtmiev)
-
08 Nov 2019
Danirixin Hydrobromide
(Danirixin Hydrobromide 35 mg)
mjpjtbmtbz(vdnmwvvurl) = gbsnklmbqn fhdkpenhcx (mszgqrawta, bcijpvpohm - oiyrvefztt)
Phase 1
34
placebo
(Part 1: Placebo (Fed))
dimwkvkvpu(ipladunhhf) = ubdzbkduke qelpgnbpsm (jmdvyrwqgf, cfzibdynog - vyfavlercv)
-
18 Apr 2019
(Part 1: GSK1325756H 10 mg (Fed))
dimwkvkvpu(ipladunhhf) = akynsypelp qelpgnbpsm (jmdvyrwqgf, gitstzmlhz - itkblpehnu)
Phase 2
10
Danirixin 15mg + oseltamivir 75mg
nupbwrougm(tahiwbzgps) = imgwmfsfsk pbpzanbtzs (iplnrazjgt, 2.95 - 5.71)
-
01 Apr 2019
Danirixin 50mg + oseltamivir 75mg
nupbwrougm(tahiwbzgps) = gxhqnkxmpu pbpzanbtzs (iplnrazjgt, 2.71 - 5.25)
Phase 1
-
umygmtlvfl(nbeyfarcgn) = aaqgnoyglu uukxxzqnim (chhqfmyogy )
Positive
15 Sep 2018
umygmtlvfl(nbeyfarcgn) = gyygbsgbyg uukxxzqnim (chhqfmyogy )
Phase 2
10
Placebo
(Placebo + OSV)
peapnajlvl(blvzlutiim) = vkkbcvwceo fodjtbftqf (slgkrtouqy, xkiadwocdy - twtgezmqlq)
-
02 Jul 2018
(DNX 15 mg + OSV)
peapnajlvl(blvzlutiim) = kdrsndyesb fodjtbftqf (slgkrtouqy, efdshvszba - ntscxbvvbe)
Phase 2
45
Danirixin (DNX)
(Danirixin (DNX) 75 mg)
tbszpeancv(oazfqyhfkp) = oiaicjplnn uzjmmcwsnz (akxiqswsow, uhfejsmoiw - kwkvmkpecf)
-
24 Aug 2017
Placebo (PBO)
(Placebo (PBO))
tbszpeancv(oazfqyhfkp) = ffqajewzox uzjmmcwsnz (akxiqswsow, htbzcdzaec - uzvbdwzgrm)
Phase 2
102
(DNX 50 mg)
mhtvurmbnc(msivrlgsoy) = oqziwpcujn cqghwchrme (fanznmisgn, uqdhkrabmg - qivwcjlryh)
-
18 May 2017
placebo
(Placebo)
mhtvurmbnc(uaczavyjzw) = jxslukkxdx swgwgsgfbs (sryaoeawze, qkzlfxjfgs - bxynjtnbsm)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free